The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
FDA places partial clinical hold on odronextamab trials in B-cell non-Hodgkin lymphomas
On December 14, 2020, it was reported that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on trials of odronextamab, a CD20 and CD3 bispecific antibody, in B-cell non-Hodgkin lymphomas (B-NHL). This was based on the incidence of ≥ Grade 3 cytokine release syndrome during step-up dosing. Therefore, enrollment into the clinical trials has paused to allow for protocol amendment to reduce the incidence of this adverse event.1
The two trials currently affected are:
- NCT02290951: a multicenter, open-label, phase I trial, investigating the safety and tolerability of odronextamab in patients with CD20+ B-NHL and chronic lymphocytic leukemia, previously treated with CD20-directed antibody therapy.1,2
- Most recent trial results were presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition and are summarized in our video interview with Rajat Bannerji.
- NCT03888105: a phase II, open-label trial, investigating the antitumor activity and safety of odronextamab in patients with relapsed/refractory B-NHL.1,3
- Most recent trial results were presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition as a poster presentation.4
Upon acceptance of the protocol amendment, patient enrollment is hoped to continue in the first quarter of 2021.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content